Aktuális MGYTávoktatási cikkek letöltése
Tartalom
Staféta
COngressus Pharmaceuticus Hungaricus XVI.
Congressus Pharmaceuticus Hungaricus XVI. programelőzetes
Továbbképző közlemények
Newman, C.B., Preiss, D., Tobert, J.A., Jacobson, T.A., Page, R.L. 2nd, Goldstein, L.B., Chin, C., Tannock, L.R., Miller, M., Raghuveer, G., Duell, P.B., Brinton, E.A., Pollak, A., Braun, L.T., Welty, F.K.; on behalf of the American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:e38–e81. doi: 10.1161/ATV.0000000000000073.
Vajer P.: Safety and adverse events of statins
The following summary is based on Statin safety and associated adverse events: a scientific statement from the American Heart Association, 2018. The most important conclusions and messages are as follows: In developed countries statins are widely prescribed to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage. Although all benefits of statin usage are well known there are serious problems with adherence. The relatively low rates in adherence are due to some misundertandings, misleading communication and false information appaering in the media. There are some facts which should be known: the risk of statin-induced serious muscle injury, including rhabdomyolysis, is <0.1%, and the risk of serious hepatotoxicity is ≈0.001%; newly diagnosed diabetes mellitus is ≈0.2% per year of treatment. In secondary prevention statins possibly increase the risk of hemorrhagic stroke; but they lead to a greater reduction in the risk of atherothrombotic stroke and thus total stroke, as well as other cardiovascular events. We do not know any evidence that would show any relationship between statins and cancer, cognitive dysfunction, peripheral neuropathy. In some countries roughly 10% of patients stop taking a statin because of subjective complaints, most commonly muscle symptoms without raised creatine kinase. In contrast, in randomized clinical trials, the difference in the incidence of muscle symptoms without significantly raised creatine kinase in statin-treated compared with placebo-treated participants is <1%, and it is even smaller (0.1%) for patients who discontinued treatment because of such muscle symptoms. This suggests that muscle symptoms are usually not caused by pharmacological effects of the statin. Overall, in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks.
Dános B., László-Bencsik Á., Boldizsár I.: Pharmaco-bota-nical Field Trip
Brantner Antal Ifjúsági Nívódíj Pályázat
1. Ávila, M., Zougagh, M., Escarpa, A., Ríos, Á.: Journal of Chromatography A 1216, 7179-7185 (2009).
2. Rietjens, I.M.C.M., Martena, M.J., Boersma, M.G., Spiegelenberg, W., Alink, G.M.: Mol. Nutr. Food Res. 49, 131-158 (2005).
3. Balogh L.: Toxikus fenil-propán származékok előfordulása és jellemzése, Semmelweis Egyetem (2016).
4. Tisserand, R., Young, R. (szerk.): Essential Oil Safety: A Guide for Health Care Professionals, Churchill Livingstone Elsevier, London (2014), pp. 147-163.
5. Salzer, U.J., Furia, T.E.: Critical Reviews in Food Science & Nutrition 9, 345-373 (1977).
6. Barceloux, D.G.: Disease-a-Month, 55, 373-379 (2009).
7. Lee, B.K., Kim, J.H., Jung, J.W., Choi, J.W., Han, E.S., Lee, S.H., Ko, K.H., Ryu, J.H.: Toxicology Letters 157, 49-56 (2005).
8. Braun, U., Kalbhen, D.A.: Pharmacology 9, 312-316 (1973).
9. Lee, H.S., Jeong, T.C., Kim, J.H.: J. Chromatogr. B: Biomed. Sci. Appl. 705, 367-372 (1998).
10. Beyer, J., Ehlers, D., Maurer, H.H.: Ther. Drug Monit. 28, 568-575 (2006).
11. Scientific Committee on Food (SCF): Opinion of the Scientific Committee on Food on Estragole (1-allyl-4-methoxybenzene), European Commission Health & Consumer Protection Directorate-General, Brussel (2001), pp. 1–10.
12. Smith, R.L., Doull, J., Feron, V.J. Goodman, J.I., Munro, I.C., Newberne, P.M., Portoghese, P.S., Waddell, W.J., Wagner, B.M., Adams, T.B., McGowen, M.M.: Food Technol. 12, 34–55 (2001).
13. Cartus, A.T., Herrmann, K., Weishaupt, L.W., Engst, W., Glatt, H., Schrenk, D.: Toxicological Sciences 129, 21-34 (2012).
14. Scientific Committee on Food (SCF): Opinion of the Scientific Committee on Food on Methyleugenol (1-allyl-1,2-dimethoxybenzene), European Commission Health & Consumer Protection Directorate-General, Brussel (2001), pp. 1–10.
15. Raffo, A., D’Aloise, A., Magrì, A.L., Leclercq, C.: Food and Chemical Toxicology 59, 626-635 (2013).
16. Scientific Committee on Food (SCF): Opinion of the Scientific Committee on Food on the safety of the presence of safrole (1-allyl-3,4-methylene dioxybenzene) in flavourings and other food ingredients with flavouring properties, European Commission Health & Consumer Protection Directorate-General, Brussel (2002), pp. 1– 10.
17. Smith, R.L., Adams, T.B., Doull, J., Feron, V.J., Goodman, J.I., Marnett, L.J., Portoghese, P.S., Waddell, W.J., Wagner, B.M., Rogers, A.E., Caldwell, J., Sipes, I.G.: Food Chem. Toxicol. 40, 851–870 (2002).
18. Kerpel-Fronius S. (szerk.): Farmakoterápia, Medicina Könyvkiadó Zrt., Budapest (2008) pp. 93-98.
19. Boberg, E.W., Miller, E.C., Miller, J.A., Poland, A., Liem, A.: Cancer Res. 43, 5163
5173 (1983).
20. Randerath, K.P., Putman, K.L., Randerath, E.: Biochem. Biophys. Res. Commun. 192, 61– 68 (1993).
21. Bodell, W.J., Ye, Q., Pathak, D.N., Pongracz, K.: Carcinogenesis 19, 437–443 (1998).
22. Stening, P., Gardner, I., Kenna, J.E., Coughtrie, M.W.H., Caldwell, J.: Human & Experimental Toxicology 16, 62 (1997).
23. Randerath, K., Haglund, R.E., Phillips, D.H., Reddy, M.V.: Carcinogenesis 5, 1613–1622 (1984).
24. Carvalho, M., Milhazes, N., Remiăo, F., Borges, F., Fernandes, E., Amado, F., Monks, T.J., Carvalho, F., Bastos, M.L.: Arch. Toxicol. 78, 16–24 (2004).
25. Nakagawa, Y., Suzuki, T., Tayama, S., Ishii, H., Ogata, A.: Arch. Toxicol. 83, 69–80 (2009).
26. Herrmann, K., Schumacher, F., Engst, W., Appel, K.E., Klein, K., Zanger, U.M., Glatt, H.: Carcinogenesis 34, 1025-1030 (2013).
Hiba-Balogh L. N., Böszörményi A.: Characterisation of toxic volatile phenylpropanoids
This paper presents an overview of the presence and characterisation of toxic volatile phenylpropanoids, namely apiol, myristicin, estragole, eugenol, methyl eugenol and safrole, naturally occurring compounds of herbs. In terms of chemical structure these compounds are alkenylbenzenes, and therefore considered as potential genotoxic and carcinogenic substances from a pharmacological point of view. For instance a metabolite of methyl eugenol (namely 1-hydroxy-methyl eugenol) has proven to be hepatocarcinogenic in vitro and in vivo. Besides these compounds are naturally occurring in herbs, food also contains phenylpropanoids as intentionally added flavouring substances (for example beverages and ice cream). Therefore the use of spices containing these toxic phenylpropanoids, require special attention.
Beszélgetősarok
Aktuális oldalak
1. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-8-ncov-cleared.pdf, (letöltve: 2020. 02. 06.) 2.
https://www.ecdc.europa.eu/en/novel-coronavirus-china, (letöltve: 2020. 02. 12.) 3.
https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea, (letöltve: 2020. 02. 12.) 4.
European Centre for Disease Prevention and Control. Personal protective equipment (PPE) needs in healthcare settings for the care of patients with suspected or confirmed 2019-nCoV. ECDC: Stockholm; 2020. https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-personal-protective-equipment-needs-healthcare-settings.pdf (letöltve: 2020. 02. 08.) 5.
European Centre for Disease Prevention and Control. Interim guidance for environmental cleaning in nonhealthcare facilities exposed to 2019-nCoV. ECDC: Stockholm; 2020. https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-guidance-environmental-cleaning-non-healthcare-facilities.pdf (letöltve: 2020. 02. 08.) 6.
https://mta.hu/tudomany_hirei/a-koronavirusrol-es-a-kialakult-jarvanyugyi-helyzetrol-targyilagosan-110308, (letöltve: 2020. 02. 06.) 7.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30185-9/fulltext, (letöltve: 2020. 02. 06.) 8.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext, (letöltve: 2020. 02. 06.) 9.
https://www.cdc.gov/coronavirus/2019-nCoV/summary.html#risk-assessment, (letöltve: 2020. 02. 06.)
Katz Z.: Important facts about 2019 Novel Coronavirus (2019-nCoV
Hírek
Dános Béla tanár úr kilencven éves – Jubileumi oklevelek átadása Szegeden – II. rész – – In memoriam